{"gene":"ETS1","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1988,"finding":"Human ETS1 encodes a protein of 441 amino acids that is >95% identical to chicken c-ets-1, establishing it as the mammalian ortholog of the v-ets oncogene protooncogene transduced by avian leukemia virus E26.","method":"cDNA sequencing and open reading frame analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing of human ETS1 cDNA, replicated across human and chicken orthologs","pmids":["2847145"],"is_preprint":false},{"year":1990,"finding":"The human ets-1 gene produces multiple protein isoforms (p51, p48, p42, p39) by at least two mechanisms: alternative splicing of exon VII and protein phosphorylation; phosphorylated forms (pp52, pp49) are found mainly in the cytoplasm, while p48 and p39 (lacking exon VII) are found mainly in the nucleus.","method":"Monoclonal antibody characterization, subcellular fractionation, PCR, and exon-specific antibodies","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (antibody, fractionation, PCR, exon mapping) in a single study","pmids":["2189104"],"is_preprint":false},{"year":1991,"finding":"The ets-1 promoter contains AP1, AP2, Sp1, and ets-1 binding sites; c-Jun enhances ets-1 promoter activity, and ets-1 positively autoregulates its own expression via an ets-binding site in its promoter.","method":"Promoter cloning, reporter transfection assays, sequence analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter analysis with reporter assays and sequence mapping, single lab","pmids":["1945412"],"is_preprint":false},{"year":1992,"finding":"The ets-1 promoter is inducible by serum and by co-expression of c-Fos and c-Jun (AP-1); a 50-bp element containing AP-1 and Ets-1 binding motifs is sufficient for this responsiveness, and Ets-1 positively autoregulates its own promoter.","method":"Promoter cloning, deletion analysis, reporter transfection assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with deletion mapping, consistent with [59], single lab","pmids":["1614856"],"is_preprint":false},{"year":1994,"finding":"Ets-1 and core binding factor (CBF) form a high-affinity ternary DNA-binding complex on the TCRβ enhancer elements beta E2 and beta E3; CBF-Ets-1-DNA complexes increase Ets-1 DNA binding affinity and decrease CBF dissociation rate; this interaction does not require fixed spacing or orientation of Ets and CBF sites.","method":"Recombinant protein binding, electrophoretic mobility shift assay (EMSA), oligonucleotide mutagenesis, binding site selection","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted ternary complex with purified proteins, mutagenesis, and kinetics in a single rigorous study","pmids":["8264651"],"is_preprint":false},{"year":1995,"finding":"Ets-1 is required for normal survival and activation of murine T cells; Ets-1-/- T cells show markedly decreased numbers of mature thymocytes and peripheral T cells, exhibit a severe proliferative defect in response to multiple activating signals, and display increased spontaneous apoptosis in vitro.","method":"RAG-2-/- blastocyst complementation, embryonic stem cell gene targeting (homozygous deletion), flow cytometry, proliferation and apoptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined cellular phenotype, replicated across two independent labs (PMIDs 7566177 and 7566176)","pmids":["7566177","7566176"],"is_preprint":false},{"year":1995,"finding":"Ets-1 deficiency causes increased T cell apoptosis and abnormally elevated terminal B cell differentiation to IgM-secreting plasma cells; Ets-1-/- T cells are present in reduced numbers and highly susceptible to cell death, while Ets-1-/- B cells are present in normal numbers but a high proportion become IgM plasma cells.","method":"RAG-2-deficient blastocyst complementation, gene targeting, flow cytometry, in vitro culture assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO, two independent groups with consistent findings","pmids":["7566176","7566177"],"is_preprint":false},{"year":1995,"finding":"Ets-1 phosphorylation in astrocytes is stimulated by neurotransmitters (bradykinin, carbachol, glutamate, norepinephrine) and is blocked by KT5926 (a myosin light-chain kinase inhibitor), implicating MLCK in ets-1 phosphorylation in vivo.","method":"Metabolic labeling, immunoprecipitation, pharmacological inhibition in primary astrocyte cultures and astrocytoma cell lines","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological approach with immunoprecipitation, single lab, consistent across multiple stimuli","pmids":["7823957"],"is_preprint":false},{"year":1996,"finding":"MafB, an AP-1-like protein expressed in myelomonocytic cells, is a direct interaction partner of Ets-1 that binds to the Ets-1 DNA-binding domain via its basic region/leucine-zipper; MafB represses Ets-1 transactivation of synthetic Ets-binding-site promoters and of the transferrin receptor promoter, thereby inhibiting Ets-1-mediated erythroid differentiation.","method":"Yeast one-hybrid screen with DNA-bound Ets-1, domain mapping, reporter transfection, overexpression in erythroblast cell line","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — yeast screen, domain mapping, functional reporter assays, and cellular differentiation readout in a single rigorous study","pmids":["8620536"],"is_preprint":false},{"year":1998,"finding":"Ets-1 binds the transcriptional coactivators CBP and p300 through N-terminal cysteine/histidine-rich regions of CBP (residues 313–452 and 1449–1892); this interaction is required for specific Ets-1 transactivation functions; the Ets-1–CBP/p300 immunocomplex possesses histone acetyltransferase activity; E1A (a CBP/p300 inhibitor) represses Ets-1-dependent promoters.","method":"Co-immunoprecipitation, GST pulldown, reporter transfection, overexpression, histone acetyltransferase assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, direct binding, enzymatic assay, and functional reporters, single lab with multiple orthogonal methods","pmids":["9528793"],"is_preprint":false},{"year":1998,"finding":"The Ets-1 PNT (Pointed) domain forms a monomeric five-helix bundle (solved by NMR); the MAP kinase phosphorylation site (Thr-38 region) is in a highly flexible, unstructured region that is not structurally altered upon phosphorylation; these findings suggest the PNT domain functions in heterotypic protein–protein interactions rather than DNA binding.","method":"NMR structure determination of a 110-residue fragment of murine Ets-1","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with functional implications, single lab but rigorous structural data","pmids":["9770451"],"is_preprint":false},{"year":1998,"finding":"Ets-1 and Ets-2 activate the uPA and MMP-9 promoters in response to EGF; activation requires composite Ets and AP-1 binding sites; overexpression of Ets-1/Ets-2 potentiates EGF-induced uPA and MMP-9 promoter activity in ErbB-2-overexpressing breast cancer cells.","method":"Reporter transfection assays, expression vector transfection, promoter mutagenesis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with site mutagenesis, gain-of-function overexpression, single lab","pmids":["9639404"],"is_preprint":false},{"year":1999,"finding":"Ets-1 and AML1 (CBFα/PEBP2αB1) directly interact via two contact points: (1) the autoinhibitory exon VII domain of Ets-1 with the NRDB of AML1, and (2) the DNA-binding domains; this interaction reciprocally relieves autoinhibition of both proteins and stimulates their DNA binding and transactivation cooperatively on the TCRβ enhancer.","method":"Co-immunoprecipitation, domain-deletion mapping, dominant-negative mutants, EMSA, reporter transactivation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal interaction mapping, dominant-negative validation, functional transactivation assays, multiple orthogonal approaches","pmids":["10075931"],"is_preprint":false},{"year":2000,"finding":"ETS1 interacts with the Daxx protein (EAP1/Daxx) via the ETS1 N-terminal 139 amino acids (Daxx Interaction Domain) and the C-terminal 173 amino acids of Daxx; this interaction represses ETS1-mediated transcriptional activation of MMP1 and BCL2 genes; both interaction domains are required for repression.","method":"Yeast two-hybrid screen, in vitro pulldown, nuclear co-localization, co-transfection reporter assays, domain deletion","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — yeast two-hybrid, in vitro binding, co-localization, and functional assays, single lab","pmids":["10698492"],"is_preprint":false},{"year":2000,"finding":"Ets-1 interacts directly with vitamin D receptor (VDR), estrogen receptor (ER), and PPARα via their respective DNA-binding domains; this interaction induces a conformational change in VDR (increased protease resistance) and enables ligand-independent, AF2-independent transcriptional activation of these nuclear receptors, as well as recruitment of coactivators to AF2-deficient mutant receptors.","method":"Co-immunoprecipitation, GST pulldown, reporter assays, limited proteolysis, domain mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding demonstrated with purified domains, conformational change assay, functional reporters, multiple receptors tested","pmids":["11073980"],"is_preprint":false},{"year":2001,"finding":"Hypoxia induces ETS-1 expression via HIF-1: deletion of a region between -424 and -279 bp of the ETS-1 promoter reduces hypoxia-mediated inducibility; HIF-1 binds to a hypoxia responsive element-like sequence in this region under hypoxic conditions; decoy oligonucleotides of this sequence inhibit hypoxia-mediated ETS-1 induction.","method":"Promoter deletion analysis, EMSA with HIF-1, decoy oligonucleotide experiments, reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion, EMSA, and functional decoy experiments, single lab","pmids":["11708773"],"is_preprint":false},{"year":2002,"finding":"Sp100 physically interacts with two regions of ETS-1 (domains A+B and D+E+F) and acts as a coactivator that strongly potentiates ETS-1 transcriptional activation of natural and Ets-focused promoters; ETS-1 overexpression alters nuclear body morphology by recruiting Sp100 away from PML nuclear bodies.","method":"Co-immunoprecipitation, GST pulldown, reporter assays, indirect immunofluorescence","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, domain mapping, functional reporters, localization studies, single lab","pmids":["11909962"],"is_preprint":false},{"year":2003,"finding":"EAPII interacts with ETS1 (and ETS2, FLI1) both in vitro and in vivo; EAPII is predominantly nuclear; EAPII negatively modulates ETS1 transcriptional activity, attenuates synergistic transactivation by ETS1 and AP-1, and re-expression of EAPII inhibits migration of epithelial cancer cells.","method":"Yeast two-hybrid, in vitro pulldown, co-immunoprecipitation, indirect immunofluorescence, reporter assays, migration assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — yeast two-hybrid, Co-IP, reporter assays, functional migration assay, single lab","pmids":["12743594"],"is_preprint":false},{"year":2004,"finding":"The autoinhibitory module of Ets-1 is formed by hydrophobic packing of N-terminal inhibitory helices (HI-1, HI-2) with C-terminal inhibitory sequences (H4, H5) and H1 of the ETS domain; HI-1 is only marginally stable (amide exchange ~15-fold slower than unfolded), and this lability enables allosteric coupling of DNA binding with HI-1 unfolding; this mechanism allows modulation of Ets-1 activity by protein partnerships, PTMs, or mutations.","method":"NMR spectroscopy, 15N relaxation studies, hydrogen exchange measurements, structure determination","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with relaxation and hydrogen exchange dynamics, rigorous structural characterization, single lab","pmids":["15591056"],"is_preprint":false},{"year":2004,"finding":"ERK2 phosphorylates Ets-1 specifically at Thr-38 within the consensus 36ΦχTPro39 sequence; the Ets-1 N-terminal tail contains a previously unrecognized docking site for ERK2 that promotes Thr-38 phosphorylation while discriminating against phosphorylation of Ser-26; Ets-1 engages both the D-recruitment site and F-recruitment site of ERK2.","method":"Fluorescence anisotropy binding assays, mutagenesis and truncation analysis, peptide displacement, in vitro phosphorylation","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, competitive peptide displacement, quantitative binding measurements, single lab with multiple orthogonal methods","pmids":["17105191"],"is_preprint":false},{"year":2004,"finding":"MAPK phosphorylation of Ets-1 and Ets-2 at a conserved site N-terminal to the PNT domain results in enhanced transactivation via preferential recruitment of CBP and p300 coactivators; both the phosphoacceptor site (in unstructured region) and the PNT domain are required for this phosphorylation-augmented interaction; CBP and Ets-2 interact in a phosphorylation-enhanced manner in vivo.","method":"Affinity chromatography screen of HeLa nuclear extracts, purified protein binding assays, reporter transactivation assays, co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — unbiased affinity screen plus direct binding with purified proteins, in vivo Co-IP, functional reporters, multiple orthogonal methods","pmids":["15572696"],"is_preprint":false},{"year":2005,"finding":"Ets-1 is required for T-bet to promote IFN-γ production in Th1 cells; Ets-1-deficient Th1 cells fail to mount effective Th1 inflammatory responses in vivo and produce abnormally high IL-10; Ets-1 acts as a functional cofactor of T-bet.","method":"Ets-1 knockout mouse, in vitro Th1 differentiation, cytokine measurement, in vivo infection model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cytokine phenotype and in vivo validation, single lab","pmids":["15728239"],"is_preprint":false},{"year":2005,"finding":"Ets-1 is a critical transcriptional mediator of Ang II-mediated vascular inflammation and remodeling; Ets1-/- mice show significantly diminished arterial wall thickening, perivascular fibrosis, and cardiac hypertrophy in response to Ang II; Ets-1 target genes p21CIP, PAI-1, and MCP-1 are identified as downstream mediators; MCP-1 is a novel Ets-1 target whose reduced expression leads to diminished T cell and macrophage recruitment to the vessel wall.","method":"Ets-1 knockout mouse, Ang II infusion model, target gene analysis, immunohistochemistry","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with defined molecular targets and in vivo phenotypic readouts, single lab","pmids":["16138193"],"is_preprint":false},{"year":2006,"finding":"Ets-1 is modified by sumoylation at lysines K15 and K227 within synergy control motifs; the E2 SUMO-conjugating enzyme Ubc9 and E3 SUMO ligase PIASy enhance sumoylation, while SUMO protease SENP1 desumoylates Ets-1; sumoylation represses Ets-1 transcriptional activity; Ets-1 is also modified by K48-linked polyubiquitination and degraded via the 26S proteasome, independently of sumoylation sites.","method":"Mutagenesis (K→R substitutions), co-transfection with SUMO pathway components, reporter assays, proteasome inhibitor treatment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — site-directed mutagenesis identifying acceptor sites, functional pathway component overexpression, proteasome experiments, single lab with multiple methods","pmids":["16862185"],"is_preprint":false},{"year":2006,"finding":"PIASy is a specific SUMO-E3 ligase for Ets-1 and a novel interaction partner; PIASy represses Ets-1-dependent transcription independently of Ets-1 sumoylation status (requiring instead sumoylation of other factors).","method":"In vivo and in vitro sumoylation assays, mutagenesis, co-immunoprecipitation, reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro/in vivo sumoylation assays, Co-IP, reporter assays; consistent with [50], single lab","pmids":["16729975"],"is_preprint":false},{"year":2007,"finding":"Ets-1 physically interacts with Blimp-1 and blocks Blimp-1 DNA binding activity and its ability to repress target genes (without affecting Blimp-1 protein levels), thereby limiting plasmacytic differentiation downstream of TLR9; Ets-1 also induces expression of Blimp-1 target genes including Pax-5.","method":"Co-immunoprecipitation, EMSA (DNA binding inhibition), reporter assays, gene expression analysis in KO B cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating physical interaction, EMSA showing functional inhibition of Blimp-1 DNA binding, KO cell validation, single lab","pmids":["17977828"],"is_preprint":false},{"year":2008,"finding":"Ets-1 DNA-binding affinity is allosterically regulated by a serine-rich region (SRR); multi-site phosphorylation of the flexible SRR in response to Ca2+ signaling enhances thermodynamic stability of the ETS domain and its inhibitory module and shifts Ets-1 to an inhibited conformation via transient intramolecular interactions between the SRR and the DNA-binding interface; paramagnetic relaxation enhancement NMR identified a preferential interaction surface.","method":"NMR spectroscopy (including paramagnetic relaxation enhancement), thermal/urea denaturation, DNA binding assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR-based structural and dynamic analysis with quantitative binding measurements and thermodynamic characterization, single lab","pmids":["18692067"],"is_preprint":false},{"year":2008,"finding":"Ets-1 forms a regulated homodimer on the stromelysin-1 promoter palindromic ETS-binding sites; the crystal structure of Ets-1 on this element reveals that homodimerization is mediated by the specific arrangement of two ETS-binding sites and requires the N-terminal flanking region; Ets-1 variants with mutations in this region lose the ability to dimerize on DNA and to transactivate the stromelysin-1 promoter.","method":"X-ray crystal structure determination, mutagenesis, EMSA, reporter transactivation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis and functional validation in a single rigorous study","pmids":["18566588"],"is_preprint":false},{"year":2008,"finding":"In erythroid cells, Ets-1 is downregulated and exported from the nucleus via a leucine-rich nuclear export signal during differentiation; in megakaryocytes, Ets-1 remains nuclear; Ets-1 overexpression blocks erythroid maturation, upregulates GATA-2, and downregulates GATA-1; Ets-1 directly binds to and activates the GATA-2 promoter in vitro and in vivo.","method":"Nuclear export signal identification, subcellular fractionation, ChIP, reporter assays, overexpression in CD34+ progenitor cells","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP (in vivo binding), reporter assays, functional overexpression with lineage differentiation readouts, nuclear export signal identification, single lab","pmids":["16294212"],"is_preprint":false},{"year":2010,"finding":"Ets-1 is required for the development and suppressive function of natural regulatory T cells (Tregs); Ets-1-/- mice develop T cell-mediated autoimmunity with reduced Treg numbers; Ets-1-/- Tregs express low Foxp3 and show decreased in vitro suppression; Ets-1 interacts with the Foxp3 intronic enhancer and is required for demethylation of this regulatory sequence.","method":"Ets-1 knockout mouse, RAG2-/- reconstitution chimeras, fetal thymic organ culture, ChIP (Foxp3 enhancer), in vitro suppression assay, IBD transfer model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, ChIP demonstrating direct enhancer occupancy, functional suppression assay, multiple in vivo models, single lab","pmids":["20855499"],"is_preprint":false},{"year":2010,"finding":"Ets-1 and Ets-2 regulate miR-126 expression in endothelial cells; a genomic region (-71 to -100 bp upstream of the miR-126 transcriptional start site) containing an Ets binding site is critical for transactivation; mutations in the Ets binding site block transactivation; knockdown of Ets-1 and Ets-2 decreases miR-126 expression.","method":"Reporter assays with promoter deletion/mutagenesis, ChIP, Ets-1/Ets-2 knockdown","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with site mutagenesis, ChIP, and siRNA knockdown, single lab","pmids":["20671229"],"is_preprint":false},{"year":2012,"finding":"Ets-1 interacts with HDAC1; co-expression of Ets-1 with HDAC1 synergistically represses IL-10 transcription in Th1 cells; Ets-1 deficiency leads to increased histone H3 acetylation and reduced HDAC1 enrichment at Il10 regulatory regions.","method":"Co-immunoprecipitation (physical interaction), chromatin immunoprecipitation (HDAC1 enrichment, H3 acetylation), reporter assays, Ets-1 KO Th1 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating physical interaction, ChIP for chromatin changes, functional reporter assays, KO cell validation, single lab","pmids":["22266280"],"is_preprint":false},{"year":2012,"finding":"ETS1 directly activates expression of ATXN2 by binding to an ETS-binding site in the ATXN2 promoter; endogenous ETS1 occupies the ATXN2 promoter (confirmed by supershift EMSA and ChIP); ETS1 overexpression increases ATXN2 expression, deletion of the ETS1-binding site abrogates this effect, and dominant-negative ETS1 or ETS1 shRNA reduce ATXN2 expression.","method":"EMSA with supershift assay, ChIP, luciferase reporter assays with promoter deletion, overexpression and dominant-negative/shRNA knockdown","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, supershift EMSA, reporter assays with mutagenesis, and gain/loss-of-function, single lab with multiple orthogonal methods","pmids":["22914732"],"is_preprint":false},{"year":2013,"finding":"Ets-1 physically and functionally interacts with NFAT proteins; Ets-1 is required for the recruitment of NFAT to the IL-2 promoter; nuclear Ets-1 exits the nucleus in response to calcium-dependent signals and competes with NFAT for binding to components of the NRON complex (a cytoplasmic trap for phosphorylated NFAT), thereby facilitating NFAT nuclear entry; Ets-1 deficiency impairs nuclear entry but not dephosphorylation of NFAT.","method":"Co-immunoprecipitation, ChIP (NFAT recruitment to IL-2 promoter), subcellular fractionation, nuclear entry assays in Ets-1-/- T cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, subcellular fractionation with functional outcome, KO validation, single lab with multiple orthogonal methods","pmids":["24019486"],"is_preprint":false},{"year":2017,"finding":"VEGF stimulates ETS1 acetylation in endothelial cells; acetylated ETS1 has enhanced chromatin occupancy and binds BRD4, which recruits the RNAPII pause-release machinery to broadly increase RNAPII pause release at transcribed genes; this ETS1-BRD4 axis is required for endothelial cell angiogenic responses in vitro and in vivo.","method":"ChIP-seq, Co-immunoprecipitation, acetylation assays, dominant-negative and knockdown experiments, in vitro angiogenesis assays, in vivo angiogenesis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq, Co-IP, acetylation assays, in vivo validation with multiple orthogonal methods in a single rigorous study","pmids":["28851877"],"is_preprint":false},{"year":2017,"finding":"The deubiquitinating enzyme Usp9x stabilizes Ets-1 by blocking its proteasomal destruction; Usp9x knockdown or inhibition reduces Ets-1 levels and suppresses Ets-1-driven NRAS expression and melanoma tumorigenicity; Usp9x and Ets-1 levels are coincidently elevated in metastatic melanoma.","method":"Ubiquitination assays, Usp9x knockdown/inhibition, Co-immunoprecipitation, gene expression analysis, in vivo tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ubiquitination assays, knockdown with functional rescue, in vivo tumor models, single lab with multiple methods","pmids":["28198367"],"is_preprint":false},{"year":2019,"finding":"ETS-1 directly binds to p-Smad3 and prevents its ubiquitination and proteasomal degradation, thereby enhancing TGF-β1/Smad3 signaling and promoting hepatocyte apoptosis; TGF-β1 induces Ets-1 expression through p-Smad2/3 binding to the Ets-1 promoter.","method":"Co-immunoprecipitation, ubiquitination assays, promoter binding analysis (ChIP for p-Smad2/3 at Ets-1 promoter), Ets-1 knockdown in primary hepatocytes and NASH mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination protection assay, ChIP, in vivo KO model, single lab","pmids":["31189885"],"is_preprint":false},{"year":2019,"finding":"Endothelial-specific deletion of Ets-1 attenuates Ang II-induced cardiac fibrosis by inhibiting endothelial-to-mesenchymal transition (EndMT); Ets-1 knockdown in H5V cells blocks TGF-β1-induced EndMT with decreased expression of Snail, Slug, Twist, and ZEB1.","method":"Endothelial-specific conditional Ets-1 knockout mouse, Ang II infusion model, in vitro Ets-1 knockdown with EndMT markers","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined molecular markers, in vitro siRNA confirmation, single lab","pmids":["30670148"],"is_preprint":false},{"year":2021,"finding":"EHF (ETS homologous factor) suppresses cancer progression by inhibiting ETS1-mediated activation of ZEB1 and ZEB2 expression; specifically, EHF-SF (short form) abrogates ETS1-mediated ZEB1 promoter activation by promoting ETS1 protein degradation.","method":"Reporter assays (ZEB1 promoter), EHF overexpression, ETS1 protein level analysis, in vivo xenograft metastasis model","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays, protein degradation measurement, in vivo metastasis assay, single lab","pmids":["33712555"],"is_preprint":false},{"year":2022,"finding":"GATA4 and ETS1 physically interact (Co-IP) and co-operatively stimulate endothelial cell enhancer activity in reporter assays; ETS1 re-directs GATA4 pioneer binding to endothelial-selective genomic regions and augments GATA4's ability to open previously inaccessible chromatin; ETS1 is enriched at endothelial-selective GATA4-occupied enhancers adjacent to endocardial genes regulated by GATA4.","method":"Co-immunoprecipitation, lineage-specific ChIP (biotin-GATA4), ATAC-seq, single-cell RNA-seq, luciferase reporter assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — Co-IP, lineage-specific ChIP-seq, chromatin accessibility assay, and functional reporters, single lab with multiple orthogonal methods","pmids":["36263775"],"is_preprint":false},{"year":2004,"finding":"STAT6 and Ets-1 form a stable complex that modulates IL-4-induced Socs-1 expression in keratinocytes; co-expression of Ets-1 with STAT6 activation strongly inhibits Socs-1 promoter-luciferase reporter activity; a composite element with STAT6 and Ets binding sequences is required for IL-4 responsiveness.","method":"Co-immunoprecipitation (physical interaction), promoter deletion/mutagenesis, reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP demonstrating physical interaction, promoter mutagenesis, reporter assays, single lab","pmids":["15199062"],"is_preprint":false}],"current_model":"ETS1 is a sequence-specific transcription factor whose DNA-binding activity is regulated by an autoinhibitory module (involving marginally stable helices HI-1/HI-2 and C-terminal inhibitory sequences flanking the ETS domain), allosteric phosphorylation of a serine-rich region by CaMKII/MLCK (inhibitory) and ERK1/2 at Thr-38 (activating, promoting CBP/p300 recruitment via the PNT domain), sumoylation at K15/K227 (repressive) and ubiquitin-proteasome degradation (counteracted by deubiquitinase Usp9x); it cooperates with AML1/CBF through mutual relief of autoinhibition, interacts with numerous co-regulators (CBP/p300, MafB, Daxx/EAP1, EAPII, Sp100, HDAC1, Blimp-1, NFAT, GATA4, STAT6, nuclear receptors), and drives expression of MMP genes, uPA, VEGF targets, GATA-2, and other invasion/angiogenesis/immune-differentiation genes; in T cells it maintains survival, Foxp3/Treg development, IL-7R expression, and IL-2 production by facilitating NFAT nuclear entry, while in B cells it restrains plasmacytic differentiation by blocking Blimp-1 DNA binding, and in endothelial cells VEGF-stimulated ETS1 acetylation enhances its binding to BRD4 to broadly promote RNAPII pause release and angiogenesis."},"narrative":{"mechanistic_narrative":"ETS1 is a sequence-specific transcription factor, the mammalian ortholog of the avian v-ets oncogene, that integrates signaling inputs to control gene programs governing lymphocyte development, vascular biology, and tumor invasion [PMID:2847145, PMID:7566177, PMID:7566176]. Its DNA-binding activity is gated by an autoinhibitory module in which marginally stable N-terminal helices (HI-1, HI-2) pack against C-terminal inhibitory sequences and the ETS domain, an arrangement whose lability allows allosteric coupling of DNA binding to conformational change [PMID:15591056]; multi-site phosphorylation of a flexible serine-rich region in response to Ca2+ signaling stabilizes this inhibited conformation through transient intramolecular contacts with the DNA-binding interface [PMID:18692067]. Activating inputs converge through the unstructured N-terminal tail and adjacent PNT domain: ERK2 docks on this region and phosphorylates Thr-38, and MAPK phosphorylation enhances transactivation by promoting preferential recruitment of the CBP/p300 coactivators [PMID:17105191, PMID:15572696]. ETS1 is further controlled post-translationally by repressive sumoylation at K15/K227, by K48-linked polyubiquitination and proteasomal degradation, and by counteracting stabilization via the deubiquitinase Usp9x [PMID:16862185, PMID:28198367]. Autoinhibition is relieved cooperatively through partnership with core binding factor/AML1, which contacts both the exon VII inhibitory domain and the ETS domain to reciprocally stimulate DNA binding on the TCRβ enhancer [PMID:8264651, PMID:10075931]. ETS1 binds an extensive set of co-regulators that tune its output, including repressors (MafB, Daxx, EAPII, HDAC1, Blimp-1) and coactivators (Sp100, nuclear receptors), and drives invasion and angiogenesis genes such as uPA, MMP-9, and GATA-2 [PMID:8620536, PMID:9528793, PMID:9639404, PMID:16294212]. In T cells ETS1 maintains survival and supports Treg/Foxp3 development and IL-2 production by facilitating NFAT nuclear entry, while in B cells it restrains plasmacytic differentiation by blocking Blimp-1 DNA binding [PMID:7566177, PMID:7566176, PMID:20855499, PMID:24019486, PMID:17977828]. In endothelial cells, VEGF-stimulated acetylation enhances ETS1 chromatin occupancy and BRD4 binding to broadly promote RNAPII pause release and angiogenesis, and ETS1 cooperates with GATA4 to direct lineage-selective enhancer activation [PMID:28851877, PMID:36263775].","teleology":[{"year":1988,"claim":"Establishing that the human gene encodes the mammalian ortholog of the v-ets oncogene defined ETS1 as a protooncogene-derived transcription factor worth dissecting mechanistically.","evidence":"cDNA sequencing and ORF analysis of human ETS1 versus chicken c-ets-1","pmids":["2847145"],"confidence":"High","gaps":["Sequence alone did not define DNA-binding specificity or regulatory mechanism","No isoform or subcellular complexity addressed"]},{"year":1990,"claim":"Demonstrating multiple isoforms arising from splicing and phosphorylation, with distinct subcellular distributions, revealed that ETS1 activity is regulated at the level of protein form and localization.","evidence":"Monoclonal antibodies, subcellular fractionation, PCR and exon-specific antibodies","pmids":["2189104"],"confidence":"High","gaps":["Functional consequences of isoform differences not resolved","Kinases responsible for phosphorylation not identified"]},{"year":1992,"claim":"Mapping AP-1-responsive and autoregulatory elements in the ETS1 promoter showed how ETS1 expression is itself wired into mitogenic signaling and positive feedback.","evidence":"Promoter cloning, deletion analysis and reporter transfection assays","pmids":["1614856","1945412"],"confidence":"Medium","gaps":["Reporter-based, single-lab evidence","Endogenous chromatin context not tested"]},{"year":1994,"claim":"Reconstitution of an ETS1-CBF ternary complex on the TCRβ enhancer established cooperative DNA binding as a core mechanism for ETS1 target selection.","evidence":"Recombinant protein binding, EMSA, oligonucleotide mutagenesis and binding kinetics","pmids":["8264651"],"confidence":"High","gaps":["Structural basis of cooperativity not yet defined","Whether autoinhibition is relieved by CBF not addressed here"]},{"year":1995,"claim":"Knockout mice defined the physiological requirement for ETS1 in T cell survival/activation and in restraining terminal B cell differentiation, linking the transcription factor to lymphocyte biology.","evidence":"Blastocyst complementation, ES-cell gene targeting, flow cytometry, proliferation and apoptosis assays (two independent labs)","pmids":["7566177","7566176"],"confidence":"High","gaps":["Direct target genes mediating the phenotypes not identified","Molecular mechanism of B cell restraint unknown at this stage"]},{"year":1998,"claim":"Identifying CBP/p300 binding and the NMR structure of the PNT domain showed that ETS1 transactivation operates via coactivator recruitment through a protein-interaction module, not the DNA-binding domain.","evidence":"Co-IP, GST pulldown, HAT assays, reporters; NMR structure of a PNT-domain fragment","pmids":["9528793","9770451"],"confidence":"High","gaps":["How phosphorylation modulates CBP recruitment not yet established","PNT-domain partners beyond CBP/p300 unknown"]},{"year":1999,"claim":"Mapping the dual ETS1-AML1 contact points demonstrated mutual relief of autoinhibition as the mechanistic basis of cooperative transactivation.","evidence":"Co-IP, domain-deletion mapping, dominant-negative mutants, EMSA, reporter assays","pmids":["10075931"],"confidence":"High","gaps":["Atomic structure of the autoinhibited state not yet resolved","Generality across other ETS1 partners not tested"]},{"year":2002,"claim":"Discovery of repressive (MafB, Daxx, EAPII) and coactivating (Sp100) interactors, together with target promoters (uPA, MMP-9, MMP1), built the picture of ETS1 as a hub for context-dependent co-regulator control of invasion genes.","evidence":"Yeast hybrid screens, GST pulldown, Co-IP, reporter and migration assays","pmids":["8620536","10698492","12743594","11909962","9639404"],"confidence":"Medium","gaps":["Many interactions rest on single-lab Co-IP/reporter data","Endogenous co-occupancy on chromatin not demonstrated"]},{"year":2004,"claim":"Structural and biochemical dissection of the autoinhibitory module, ERK2 docking/Thr-38 phosphorylation, and phosphorylation-enhanced CBP/p300 recruitment defined the allosteric logic linking signaling to ETS1 output.","evidence":"NMR with relaxation/hydrogen exchange; in vitro kinase, fluorescence anisotropy, affinity chromatography, Co-IP and reporters","pmids":["15591056","17105191","15572696"],"confidence":"High","gaps":["In vivo dynamics of autoinhibition during signaling not directly measured","Quantitative contribution of each PTM in cells unresolved"]},{"year":2006,"claim":"Identification of sumoylation, polyubiquitination/proteasomal degradation, and SUMO-pathway enzymes established post-translational turnover and SUMO marking as repressive controls on ETS1 abundance and activity.","evidence":"K→R mutagenesis, SUMO-pathway co-transfection, reporter assays, proteasome inhibition, Co-IP","pmids":["16862185","16729975"],"confidence":"High","gaps":["Physiological signals triggering sumoylation not defined","Identity of the responsible ubiquitin ligase not established"]},{"year":2008,"claim":"NMR/PRE analysis of serine-rich-region phosphorylation, the crystal structure of DNA-dependent homodimerization, and the GATA-2 regulatory axis linked Ca2+ signaling, DNA architecture, and hematopoietic lineage choice to ETS1 conformation.","evidence":"NMR with PRE, denaturation and DNA-binding assays; X-ray crystallography, EMSA, ChIP and reporters","pmids":["18692067","18566588","16294212"],"confidence":"High","gaps":["In vivo prevalence of the homodimeric mode unquantified","Cross-talk between SRR phosphorylation and partner binding not fully mapped"]},{"year":2013,"claim":"T-cell studies showed ETS1 acts through partner transcription factors—as a T-bet cofactor, an HDAC1-recruiting IL-10 repressor, a Foxp3-enhancer-occupying Treg determinant, and an NFAT nuclear-entry facilitator—explaining its immunological phenotypes mechanistically.","evidence":"KO mice, ChIP, Co-IP, subcellular fractionation, suppression and cytokine assays","pmids":["15728239","22266280","20855499","24019486","17977828"],"confidence":"High","gaps":["How a single factor coordinates opposing activating/repressive roles unresolved","Direct structural basis of NFAT/Blimp-1 binding not defined"]},{"year":2017,"claim":"VEGF-induced acetylation coupling ETS1 to BRD4 and RNAPII pause release, and Usp9x-mediated stabilization driving NRAS in melanoma, revealed acetylation and deubiquitination as activating switches controlling angiogenic and oncogenic programs.","evidence":"ChIP-seq, Co-IP, acetylation/ubiquitination assays, knockdown, in vitro and in vivo angiogenesis and tumor models","pmids":["28851877","28198367"],"confidence":"High","gaps":["Acetyltransferase responsible for ETS1 acetylation not identified","Generality of pause-release mechanism beyond endothelium untested"]},{"year":2022,"claim":"Demonstrating that ETS1 redirects GATA4 pioneer binding to open lineage-selective enhancers showed ETS1 functions as a partner that shapes chromatin accessibility for tissue-specific gene programs.","evidence":"Co-IP, lineage-specific ChIP, ATAC-seq, scRNA-seq, reporter assays","pmids":["36263775"],"confidence":"High","gaps":["Mechanism by which ETS1 biases pioneer binding not resolved","Whether this cooperativity generalizes to other pioneer factors unknown"]},{"year":null,"claim":"How the many regulatory layers—autoinhibition, multi-site phosphorylation, sumoylation, ubiquitination, acetylation, and dozens of partner interactions—are integrated in vivo to specify a given ETS1 target program in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM state to genome-wide occupancy","Stoichiometry and temporal order of competing partner interactions unknown","Acetyltransferase and ubiquitin ligase identities incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,9,27,28,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,27,28,32]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[12,25,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,16,28,33]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,28,33]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,9,28,34]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,21,29,33]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[19,20,33,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[28,39]}],"complexes":[],"partners":["RUNX1","CREBBP","EP300","MAFB","DAXX","BRD4","GATA4","NFAT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P14921","full_name":"Protein C-ets-1","aliases":["p54"],"length_aa":441,"mass_kda":50.4,"function":"Transcription factor (PubMed:10698492, PubMed:11909962). Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts (PubMed:20378371). May control the differentiation, survival and proliferation of lymphoid cells (PubMed:20378371). May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion (PubMed:15247905, PubMed:15592518) Acts as a dominant-negative for isoform c-ETS-1A","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P14921/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ETS1","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ETS1","total_profiled":1310},"omim":[{"mim_id":"620738","title":"ZONE OF POLARIZING ACTIVITY REGULATORY SEQUENCE; ZRS","url":"https://www.omim.org/entry/620738"},{"mim_id":"620481","title":"AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL, 2; CAMT2","url":"https://www.omim.org/entry/620481"},{"mim_id":"612219","title":"EWING SARCOMA; ES","url":"https://www.omim.org/entry/612219"},{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"611585","title":"TESCALCIN; TESC","url":"https://www.omim.org/entry/611585"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":253.0}],"url":"https://www.proteinatlas.org/search/ETS1"},"hgnc":{"alias_symbol":["FLJ10768","ETS-1"],"prev_symbol":["EWSR2"]},"alphafold":{"accession":"P14921","domains":[{"cath_id":"1.10.150.50","chopping":"43-136","consensus_level":"high","plddt":83.3763,"start":43,"end":136},{"cath_id":"1.10.10.10","chopping":"305-434","consensus_level":"high","plddt":91.9291,"start":305,"end":434}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14921","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14921-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14921-F1-predicted_aligned_error_v6.png","plddt_mean":65.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ETS1","jax_strain_url":"https://www.jax.org/strain/search?query=ETS1"},"sequence":{"accession":"P14921","fasta_url":"https://rest.uniprot.org/uniprotkb/P14921.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14921/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14921"}},"corpus_meta":[{"pmid":"12971829","id":"PMC_12971829","title":"The biology of the Ets1 proto-oncogene.","date":"2003","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12971829","citation_count":414,"is_preprint":false},{"pmid":"7566177","id":"PMC_7566177","title":"Defective activation and survival of T cells lacking the Ets-1 transcription factor.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566177","citation_count":320,"is_preprint":false},{"pmid":"2847145","id":"PMC_2847145","title":"Mammalian ets-1 and ets-2 genes encode highly conserved proteins.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2847145","citation_count":303,"is_preprint":false},{"pmid":"7566176","id":"PMC_7566176","title":"Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566176","citation_count":298,"is_preprint":false},{"pmid":"8620536","id":"PMC_8620536","title":"MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8620536","citation_count":255,"is_preprint":false},{"pmid":"10075931","id":"PMC_10075931","title":"Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10075931","citation_count":206,"is_preprint":false},{"pmid":"8264651","id":"PMC_8264651","title":"Cooperative binding of Ets-1 and core binding factor to DNA.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8264651","citation_count":204,"is_preprint":false},{"pmid":"9639404","id":"PMC_9639404","title":"The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9639404","citation_count":194,"is_preprint":false},{"pmid":"8183549","id":"PMC_8183549","title":"Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8183549","citation_count":191,"is_preprint":false},{"pmid":"16138193","id":"PMC_16138193","title":"Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16138193","citation_count":190,"is_preprint":false},{"pmid":"9528793","id":"PMC_9528793","title":"A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9528793","citation_count":180,"is_preprint":false},{"pmid":"15572696","id":"PMC_15572696","title":"Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15572696","citation_count":172,"is_preprint":false},{"pmid":"10698492","id":"PMC_10698492","title":"EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10698492","citation_count":157,"is_preprint":false},{"pmid":"11708773","id":"PMC_11708773","title":"Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11708773","citation_count":137,"is_preprint":false},{"pmid":"20671229","id":"PMC_20671229","title":"Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells.","date":"2010","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20671229","citation_count":131,"is_preprint":false},{"pmid":"2189104","id":"PMC_2189104","title":"Isoforms of the human ets-1 protein: generation by alternative splicing and differential phosphorylation.","date":"1990","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2189104","citation_count":130,"is_preprint":false},{"pmid":"9770451","id":"PMC_9770451","title":"Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9770451","citation_count":126,"is_preprint":false},{"pmid":"20855499","id":"PMC_20855499","title":"The Ets-1 transcription factor controls the development and function of natural regulatory T cells.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20855499","citation_count":108,"is_preprint":false},{"pmid":"15728239","id":"PMC_15728239","title":"Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15728239","citation_count":105,"is_preprint":false},{"pmid":"28851877","id":"PMC_28851877","title":"VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28851877","citation_count":103,"is_preprint":false},{"pmid":"16051621","id":"PMC_16051621","title":"Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease.","date":"2005","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16051621","citation_count":101,"is_preprint":false},{"pmid":"8952528","id":"PMC_8952528","title":"Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion.","date":"1996","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8952528","citation_count":101,"is_preprint":false},{"pmid":"14704859","id":"PMC_14704859","title":"The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma.","date":"2004","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/14704859","citation_count":100,"is_preprint":false},{"pmid":"18272346","id":"PMC_18272346","title":"Mechanical strain induces osteogenic differentiation: Cbfa1 and Ets-1 expression in stretched rat mesenchymal stem cells.","date":"2008","source":"International journal of oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18272346","citation_count":92,"is_preprint":false},{"pmid":"20378371","id":"PMC_20378371","title":"Transcription factor Ets-1 in cytokine and chemokine gene regulation.","date":"2010","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/20378371","citation_count":84,"is_preprint":false},{"pmid":"15591056","id":"PMC_15591056","title":"The structural and dynamic basis of Ets-1 DNA binding autoinhibition.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15591056","citation_count":84,"is_preprint":false},{"pmid":"33344446","id":"PMC_33344446","title":"MicroRNA-221/222 Mediates ADSC-Exosome-Induced Cardioprotection Against Ischemia/Reperfusion by Targeting PUMA and ETS-1.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33344446","citation_count":84,"is_preprint":false},{"pmid":"17977828","id":"PMC_17977828","title":"Ets-1 regulates plasma cell differentiation by interfering with the activity of the transcription factor Blimp-1.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17977828","citation_count":84,"is_preprint":false},{"pmid":"12637368","id":"PMC_12637368","title":"Ets-1 and Ets-2 transcription factors are essential for normal coronary and myocardial development in chicken embryos.","date":"2003","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/12637368","citation_count":77,"is_preprint":false},{"pmid":"11103822","id":"PMC_11103822","title":"Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11103822","citation_count":76,"is_preprint":false},{"pmid":"23268366","id":"PMC_23268366","title":"MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.","date":"2012","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23268366","citation_count":75,"is_preprint":false},{"pmid":"11353051","id":"PMC_11353051","title":"Expression of the ets-1 proto-oncogene in human colorectal carcinoma.","date":"2001","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/11353051","citation_count":74,"is_preprint":false},{"pmid":"30114438","id":"PMC_30114438","title":"ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30114438","citation_count":73,"is_preprint":false},{"pmid":"16670084","id":"PMC_16670084","title":"Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16670084","citation_count":71,"is_preprint":false},{"pmid":"9486138","id":"PMC_9486138","title":"Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9486138","citation_count":71,"is_preprint":false},{"pmid":"22971289","id":"PMC_22971289","title":"Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.","date":"2012","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/22971289","citation_count":70,"is_preprint":false},{"pmid":"21423203","id":"PMC_21423203","title":"Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21423203","citation_count":63,"is_preprint":false},{"pmid":"11909962","id":"PMC_11909962","title":"Sp100 interacts with ETS-1 and stimulates its transcriptional activity.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11909962","citation_count":61,"is_preprint":false},{"pmid":"28198367","id":"PMC_28198367","title":"Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28198367","citation_count":57,"is_preprint":false},{"pmid":"14734780","id":"PMC_14734780","title":"Ets-1 regulates TNF-alpha-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14734780","citation_count":57,"is_preprint":false},{"pmid":"12743594","id":"PMC_12743594","title":"EAPII interacts with ETS1 and modulates its transcriptional function.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12743594","citation_count":57,"is_preprint":false},{"pmid":"15940256","id":"PMC_15940256","title":"Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15940256","citation_count":57,"is_preprint":false},{"pmid":"15693893","id":"PMC_15693893","title":"Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas.","date":"2005","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/15693893","citation_count":56,"is_preprint":false},{"pmid":"10218628","id":"PMC_10218628","title":"Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors.","date":"1999","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10218628","citation_count":52,"is_preprint":false},{"pmid":"18692067","id":"PMC_18692067","title":"The affinity of Ets-1 for DNA is modulated by phosphorylation through transient interactions of an unstructured region.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18692067","citation_count":52,"is_preprint":false},{"pmid":"21428970","id":"PMC_21428970","title":"Altered levels of Ets-1 transcription factor and matrix metalloproteinases in melanocytes from patients with vitiligo.","date":"2011","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21428970","citation_count":51,"is_preprint":false},{"pmid":"1614856","id":"PMC_1614856","title":"Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter.","date":"1992","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1614856","citation_count":51,"is_preprint":false},{"pmid":"15111329","id":"PMC_15111329","title":"Transcription factor Ets-1 mediates ischemia- and vascular endothelial growth factor-dependent retinal neovascularization.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15111329","citation_count":50,"is_preprint":false},{"pmid":"18566588","id":"PMC_18566588","title":"Regulation of the transcription factor Ets-1 by DNA-mediated homo-dimerization.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18566588","citation_count":50,"is_preprint":false},{"pmid":"16862185","id":"PMC_16862185","title":"Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16862185","citation_count":49,"is_preprint":false},{"pmid":"16294212","id":"PMC_16294212","title":"Overexpression of Ets-1 in human hematopoietic progenitor cells blocks erythroid and promotes megakaryocytic differentiation.","date":"2005","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16294212","citation_count":49,"is_preprint":false},{"pmid":"12915311","id":"PMC_12915311","title":"Ets-1 expression is associated with cranial neural crest migration and vasculogenesis in the chick embryo.","date":"2003","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12915311","citation_count":47,"is_preprint":false},{"pmid":"21042593","id":"PMC_21042593","title":"Ets-1 regulates energy metabolism in cancer cells.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21042593","citation_count":47,"is_preprint":false},{"pmid":"31265880","id":"PMC_31265880","title":"Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31265880","citation_count":46,"is_preprint":false},{"pmid":"11795259","id":"PMC_11795259","title":"Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis.","date":"2001","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11795259","citation_count":46,"is_preprint":false},{"pmid":"21148801","id":"PMC_21148801","title":"Ets-1 maintains IL-7 receptor expression in peripheral T cells.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21148801","citation_count":46,"is_preprint":false},{"pmid":"24019486","id":"PMC_24019486","title":"Ets-1 facilitates nuclear entry of NFAT proteins and their recruitment to the IL-2 promoter.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24019486","citation_count":46,"is_preprint":false},{"pmid":"22366814","id":"PMC_22366814","title":"ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22366814","citation_count":45,"is_preprint":false},{"pmid":"1945412","id":"PMC_1945412","title":"Structural and functional analysis of the regulatory sequences of the ets-1 gene.","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1945412","citation_count":45,"is_preprint":false},{"pmid":"24238102","id":"PMC_24238102","title":"Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24238102","citation_count":45,"is_preprint":false},{"pmid":"10392639","id":"PMC_10392639","title":"Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors.","date":"1999","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/10392639","citation_count":44,"is_preprint":false},{"pmid":"25085587","id":"PMC_25085587","title":"MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25085587","citation_count":43,"is_preprint":false},{"pmid":"12660815","id":"PMC_12660815","title":"Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12660815","citation_count":42,"is_preprint":false},{"pmid":"18851945","id":"PMC_18851945","title":"Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18851945","citation_count":40,"is_preprint":false},{"pmid":"26826553","id":"PMC_26826553","title":"miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26826553","citation_count":40,"is_preprint":false},{"pmid":"17105191","id":"PMC_17105191","title":"Properties and regulation of a transiently assembled ERK2.Ets-1 signaling complex.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17105191","citation_count":40,"is_preprint":false},{"pmid":"29773901","id":"PMC_29773901","title":"Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29773901","citation_count":39,"is_preprint":false},{"pmid":"11073980","id":"PMC_11073980","title":"Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11073980","citation_count":39,"is_preprint":false},{"pmid":"22266280","id":"PMC_22266280","title":"Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cells.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22266280","citation_count":39,"is_preprint":false},{"pmid":"11068545","id":"PMC_11068545","title":"Expression and possible role of ets-1 in hepatocellular carcinoma.","date":"2000","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11068545","citation_count":39,"is_preprint":false},{"pmid":"15574387","id":"PMC_15574387","title":"The transcription factor Ets-1 in breast cancer.","date":"2005","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/15574387","citation_count":38,"is_preprint":false},{"pmid":"11095647","id":"PMC_11095647","title":"Renal expression of the Ets-1 proto-oncogene during progression of rat crescentic glomerulonephritis.","date":"2000","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11095647","citation_count":37,"is_preprint":false},{"pmid":"11829472","id":"PMC_11829472","title":"Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11829472","citation_count":37,"is_preprint":false},{"pmid":"18855726","id":"PMC_18855726","title":"The transcription factor ETS-1: its role in tumour development and strategies for its inhibition.","date":"2008","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18855726","citation_count":36,"is_preprint":false},{"pmid":"30365153","id":"PMC_30365153","title":"Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30365153","citation_count":36,"is_preprint":false},{"pmid":"19154409","id":"PMC_19154409","title":"Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19154409","citation_count":36,"is_preprint":false},{"pmid":"7823957","id":"PMC_7823957","title":"ets-1 in astrocytes: expression and transmitter-evoked phosphorylation.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7823957","citation_count":35,"is_preprint":false},{"pmid":"21225469","id":"PMC_21225469","title":"Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells.","date":"2010","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/21225469","citation_count":34,"is_preprint":false},{"pmid":"26861134","id":"PMC_26861134","title":"Negative Correlation Between miR-326 and Ets-1 in Regulatory T Cells from new-Onset SLE Patients.","date":"2016","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26861134","citation_count":34,"is_preprint":false},{"pmid":"18181172","id":"PMC_18181172","title":"Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18181172","citation_count":34,"is_preprint":false},{"pmid":"15579511","id":"PMC_15579511","title":"Expression and function of Ets-1 during experimental acute renal failure in rats.","date":"2004","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/15579511","citation_count":33,"is_preprint":false},{"pmid":"25929465","id":"PMC_25929465","title":"TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25929465","citation_count":32,"is_preprint":false},{"pmid":"21439064","id":"PMC_21439064","title":"Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis.","date":"2011","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/21439064","citation_count":32,"is_preprint":false},{"pmid":"30670148","id":"PMC_30670148","title":"Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.","date":"2019","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/30670148","citation_count":32,"is_preprint":false},{"pmid":"12076271","id":"PMC_12076271","title":"Ets-1 and integrin beta3 for lung metastasis from colorectal cancer.","date":"2002","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/12076271","citation_count":31,"is_preprint":false},{"pmid":"25865496","id":"PMC_25865496","title":"Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25865496","citation_count":31,"is_preprint":false},{"pmid":"31189885","id":"PMC_31189885","title":"Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-β1 signaling-mediated hepatocyte apoptosis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31189885","citation_count":30,"is_preprint":false},{"pmid":"24658012","id":"PMC_24658012","title":"MicroRNA-146a and Ets-1 gene polymorphisms are associated with pediatric uveitis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24658012","citation_count":30,"is_preprint":false},{"pmid":"22914732","id":"PMC_22914732","title":"ETS1 regulates the expression of ATXN2.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22914732","citation_count":30,"is_preprint":false},{"pmid":"15199062","id":"PMC_15199062","title":"STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in keratinocytes.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15199062","citation_count":30,"is_preprint":false},{"pmid":"12168840","id":"PMC_12168840","title":"Expression of ets-1 and ets-2 in colonic neoplasms.","date":"2002","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12168840","citation_count":30,"is_preprint":false},{"pmid":"24706481","id":"PMC_24706481","title":"Ets-1 controls breast cancer cell balance between invasion and growth.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24706481","citation_count":29,"is_preprint":false},{"pmid":"21296190","id":"PMC_21296190","title":"The dual nature of Ets-1: focus to the pathogenesis of systemic lupus erythematosus.","date":"2011","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21296190","citation_count":29,"is_preprint":false},{"pmid":"27349463","id":"PMC_27349463","title":"MicroRNA221-3p modulates Ets-1 expression in synovial fibroblasts from patients with osteoarthritis of temporomandibular joint.","date":"2016","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/27349463","citation_count":29,"is_preprint":false},{"pmid":"16729975","id":"PMC_16729975","title":"PIASy-mediated repression of the Ets-1 is independent of its sumoylation.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16729975","citation_count":29,"is_preprint":false},{"pmid":"33712555","id":"PMC_33712555","title":"EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33712555","citation_count":29,"is_preprint":false},{"pmid":"35926374","id":"PMC_35926374","title":"ETS-1 facilitates Th1 cell-mediated mucosal inflammation in inflammatory bowel diseases through upregulating CIRBP.","date":"2022","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/35926374","citation_count":28,"is_preprint":false},{"pmid":"19091791","id":"PMC_19091791","title":"Ets-1 mediates platelet-derived growth factor-BB-induced thrombomodulin expression in human vascular smooth muscle cells.","date":"2008","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19091791","citation_count":28,"is_preprint":false},{"pmid":"16738537","id":"PMC_16738537","title":"Transcription factor Ets-1 is essential for mesangial matrix remodeling.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16738537","citation_count":28,"is_preprint":false},{"pmid":"36263775","id":"PMC_36263775","title":"GATA4 Regulates Developing Endocardium Through Interaction With ETS1.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36263775","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50674,"output_tokens":10340,"usd":0.153561,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20666,"output_tokens":4883,"usd":0.112702,"stage2_stop_reason":"end_turn"},"total_usd":0.266263,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"Human ETS1 encodes a protein of 441 amino acids that is >95% identical to chicken c-ets-1, establishing it as the mammalian ortholog of the v-ets oncogene protooncogene transduced by avian leukemia virus E26.\",\n      \"method\": \"cDNA sequencing and open reading frame analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing of human ETS1 cDNA, replicated across human and chicken orthologs\",\n      \"pmids\": [\"2847145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The human ets-1 gene produces multiple protein isoforms (p51, p48, p42, p39) by at least two mechanisms: alternative splicing of exon VII and protein phosphorylation; phosphorylated forms (pp52, pp49) are found mainly in the cytoplasm, while p48 and p39 (lacking exon VII) are found mainly in the nucleus.\",\n      \"method\": \"Monoclonal antibody characterization, subcellular fractionation, PCR, and exon-specific antibodies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (antibody, fractionation, PCR, exon mapping) in a single study\",\n      \"pmids\": [\"2189104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The ets-1 promoter contains AP1, AP2, Sp1, and ets-1 binding sites; c-Jun enhances ets-1 promoter activity, and ets-1 positively autoregulates its own expression via an ets-binding site in its promoter.\",\n      \"method\": \"Promoter cloning, reporter transfection assays, sequence analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter analysis with reporter assays and sequence mapping, single lab\",\n      \"pmids\": [\"1945412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The ets-1 promoter is inducible by serum and by co-expression of c-Fos and c-Jun (AP-1); a 50-bp element containing AP-1 and Ets-1 binding motifs is sufficient for this responsiveness, and Ets-1 positively autoregulates its own promoter.\",\n      \"method\": \"Promoter cloning, deletion analysis, reporter transfection assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with deletion mapping, consistent with [59], single lab\",\n      \"pmids\": [\"1614856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Ets-1 and core binding factor (CBF) form a high-affinity ternary DNA-binding complex on the TCRβ enhancer elements beta E2 and beta E3; CBF-Ets-1-DNA complexes increase Ets-1 DNA binding affinity and decrease CBF dissociation rate; this interaction does not require fixed spacing or orientation of Ets and CBF sites.\",\n      \"method\": \"Recombinant protein binding, electrophoretic mobility shift assay (EMSA), oligonucleotide mutagenesis, binding site selection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted ternary complex with purified proteins, mutagenesis, and kinetics in a single rigorous study\",\n      \"pmids\": [\"8264651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Ets-1 is required for normal survival and activation of murine T cells; Ets-1-/- T cells show markedly decreased numbers of mature thymocytes and peripheral T cells, exhibit a severe proliferative defect in response to multiple activating signals, and display increased spontaneous apoptosis in vitro.\",\n      \"method\": \"RAG-2-/- blastocyst complementation, embryonic stem cell gene targeting (homozygous deletion), flow cytometry, proliferation and apoptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined cellular phenotype, replicated across two independent labs (PMIDs 7566177 and 7566176)\",\n      \"pmids\": [\"7566177\", \"7566176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Ets-1 deficiency causes increased T cell apoptosis and abnormally elevated terminal B cell differentiation to IgM-secreting plasma cells; Ets-1-/- T cells are present in reduced numbers and highly susceptible to cell death, while Ets-1-/- B cells are present in normal numbers but a high proportion become IgM plasma cells.\",\n      \"method\": \"RAG-2-deficient blastocyst complementation, gene targeting, flow cytometry, in vitro culture assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO, two independent groups with consistent findings\",\n      \"pmids\": [\"7566176\", \"7566177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Ets-1 phosphorylation in astrocytes is stimulated by neurotransmitters (bradykinin, carbachol, glutamate, norepinephrine) and is blocked by KT5926 (a myosin light-chain kinase inhibitor), implicating MLCK in ets-1 phosphorylation in vivo.\",\n      \"method\": \"Metabolic labeling, immunoprecipitation, pharmacological inhibition in primary astrocyte cultures and astrocytoma cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological approach with immunoprecipitation, single lab, consistent across multiple stimuli\",\n      \"pmids\": [\"7823957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MafB, an AP-1-like protein expressed in myelomonocytic cells, is a direct interaction partner of Ets-1 that binds to the Ets-1 DNA-binding domain via its basic region/leucine-zipper; MafB represses Ets-1 transactivation of synthetic Ets-binding-site promoters and of the transferrin receptor promoter, thereby inhibiting Ets-1-mediated erythroid differentiation.\",\n      \"method\": \"Yeast one-hybrid screen with DNA-bound Ets-1, domain mapping, reporter transfection, overexpression in erythroblast cell line\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — yeast screen, domain mapping, functional reporter assays, and cellular differentiation readout in a single rigorous study\",\n      \"pmids\": [\"8620536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Ets-1 binds the transcriptional coactivators CBP and p300 through N-terminal cysteine/histidine-rich regions of CBP (residues 313–452 and 1449–1892); this interaction is required for specific Ets-1 transactivation functions; the Ets-1–CBP/p300 immunocomplex possesses histone acetyltransferase activity; E1A (a CBP/p300 inhibitor) represses Ets-1-dependent promoters.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, reporter transfection, overexpression, histone acetyltransferase assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, direct binding, enzymatic assay, and functional reporters, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9528793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The Ets-1 PNT (Pointed) domain forms a monomeric five-helix bundle (solved by NMR); the MAP kinase phosphorylation site (Thr-38 region) is in a highly flexible, unstructured region that is not structurally altered upon phosphorylation; these findings suggest the PNT domain functions in heterotypic protein–protein interactions rather than DNA binding.\",\n      \"method\": \"NMR structure determination of a 110-residue fragment of murine Ets-1\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with functional implications, single lab but rigorous structural data\",\n      \"pmids\": [\"9770451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Ets-1 and Ets-2 activate the uPA and MMP-9 promoters in response to EGF; activation requires composite Ets and AP-1 binding sites; overexpression of Ets-1/Ets-2 potentiates EGF-induced uPA and MMP-9 promoter activity in ErbB-2-overexpressing breast cancer cells.\",\n      \"method\": \"Reporter transfection assays, expression vector transfection, promoter mutagenesis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with site mutagenesis, gain-of-function overexpression, single lab\",\n      \"pmids\": [\"9639404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Ets-1 and AML1 (CBFα/PEBP2αB1) directly interact via two contact points: (1) the autoinhibitory exon VII domain of Ets-1 with the NRDB of AML1, and (2) the DNA-binding domains; this interaction reciprocally relieves autoinhibition of both proteins and stimulates their DNA binding and transactivation cooperatively on the TCRβ enhancer.\",\n      \"method\": \"Co-immunoprecipitation, domain-deletion mapping, dominant-negative mutants, EMSA, reporter transactivation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal interaction mapping, dominant-negative validation, functional transactivation assays, multiple orthogonal approaches\",\n      \"pmids\": [\"10075931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ETS1 interacts with the Daxx protein (EAP1/Daxx) via the ETS1 N-terminal 139 amino acids (Daxx Interaction Domain) and the C-terminal 173 amino acids of Daxx; this interaction represses ETS1-mediated transcriptional activation of MMP1 and BCL2 genes; both interaction domains are required for repression.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro pulldown, nuclear co-localization, co-transfection reporter assays, domain deletion\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — yeast two-hybrid, in vitro binding, co-localization, and functional assays, single lab\",\n      \"pmids\": [\"10698492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Ets-1 interacts directly with vitamin D receptor (VDR), estrogen receptor (ER), and PPARα via their respective DNA-binding domains; this interaction induces a conformational change in VDR (increased protease resistance) and enables ligand-independent, AF2-independent transcriptional activation of these nuclear receptors, as well as recruitment of coactivators to AF2-deficient mutant receptors.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, reporter assays, limited proteolysis, domain mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding demonstrated with purified domains, conformational change assay, functional reporters, multiple receptors tested\",\n      \"pmids\": [\"11073980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Hypoxia induces ETS-1 expression via HIF-1: deletion of a region between -424 and -279 bp of the ETS-1 promoter reduces hypoxia-mediated inducibility; HIF-1 binds to a hypoxia responsive element-like sequence in this region under hypoxic conditions; decoy oligonucleotides of this sequence inhibit hypoxia-mediated ETS-1 induction.\",\n      \"method\": \"Promoter deletion analysis, EMSA with HIF-1, decoy oligonucleotide experiments, reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion, EMSA, and functional decoy experiments, single lab\",\n      \"pmids\": [\"11708773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Sp100 physically interacts with two regions of ETS-1 (domains A+B and D+E+F) and acts as a coactivator that strongly potentiates ETS-1 transcriptional activation of natural and Ets-focused promoters; ETS-1 overexpression alters nuclear body morphology by recruiting Sp100 away from PML nuclear bodies.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, reporter assays, indirect immunofluorescence\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, domain mapping, functional reporters, localization studies, single lab\",\n      \"pmids\": [\"11909962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EAPII interacts with ETS1 (and ETS2, FLI1) both in vitro and in vivo; EAPII is predominantly nuclear; EAPII negatively modulates ETS1 transcriptional activity, attenuates synergistic transactivation by ETS1 and AP-1, and re-expression of EAPII inhibits migration of epithelial cancer cells.\",\n      \"method\": \"Yeast two-hybrid, in vitro pulldown, co-immunoprecipitation, indirect immunofluorescence, reporter assays, migration assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — yeast two-hybrid, Co-IP, reporter assays, functional migration assay, single lab\",\n      \"pmids\": [\"12743594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The autoinhibitory module of Ets-1 is formed by hydrophobic packing of N-terminal inhibitory helices (HI-1, HI-2) with C-terminal inhibitory sequences (H4, H5) and H1 of the ETS domain; HI-1 is only marginally stable (amide exchange ~15-fold slower than unfolded), and this lability enables allosteric coupling of DNA binding with HI-1 unfolding; this mechanism allows modulation of Ets-1 activity by protein partnerships, PTMs, or mutations.\",\n      \"method\": \"NMR spectroscopy, 15N relaxation studies, hydrogen exchange measurements, structure determination\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with relaxation and hydrogen exchange dynamics, rigorous structural characterization, single lab\",\n      \"pmids\": [\"15591056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERK2 phosphorylates Ets-1 specifically at Thr-38 within the consensus 36ΦχTPro39 sequence; the Ets-1 N-terminal tail contains a previously unrecognized docking site for ERK2 that promotes Thr-38 phosphorylation while discriminating against phosphorylation of Ser-26; Ets-1 engages both the D-recruitment site and F-recruitment site of ERK2.\",\n      \"method\": \"Fluorescence anisotropy binding assays, mutagenesis and truncation analysis, peptide displacement, in vitro phosphorylation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, competitive peptide displacement, quantitative binding measurements, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"17105191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MAPK phosphorylation of Ets-1 and Ets-2 at a conserved site N-terminal to the PNT domain results in enhanced transactivation via preferential recruitment of CBP and p300 coactivators; both the phosphoacceptor site (in unstructured region) and the PNT domain are required for this phosphorylation-augmented interaction; CBP and Ets-2 interact in a phosphorylation-enhanced manner in vivo.\",\n      \"method\": \"Affinity chromatography screen of HeLa nuclear extracts, purified protein binding assays, reporter transactivation assays, co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — unbiased affinity screen plus direct binding with purified proteins, in vivo Co-IP, functional reporters, multiple orthogonal methods\",\n      \"pmids\": [\"15572696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ets-1 is required for T-bet to promote IFN-γ production in Th1 cells; Ets-1-deficient Th1 cells fail to mount effective Th1 inflammatory responses in vivo and produce abnormally high IL-10; Ets-1 acts as a functional cofactor of T-bet.\",\n      \"method\": \"Ets-1 knockout mouse, in vitro Th1 differentiation, cytokine measurement, in vivo infection model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cytokine phenotype and in vivo validation, single lab\",\n      \"pmids\": [\"15728239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ets-1 is a critical transcriptional mediator of Ang II-mediated vascular inflammation and remodeling; Ets1-/- mice show significantly diminished arterial wall thickening, perivascular fibrosis, and cardiac hypertrophy in response to Ang II; Ets-1 target genes p21CIP, PAI-1, and MCP-1 are identified as downstream mediators; MCP-1 is a novel Ets-1 target whose reduced expression leads to diminished T cell and macrophage recruitment to the vessel wall.\",\n      \"method\": \"Ets-1 knockout mouse, Ang II infusion model, target gene analysis, immunohistochemistry\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with defined molecular targets and in vivo phenotypic readouts, single lab\",\n      \"pmids\": [\"16138193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ets-1 is modified by sumoylation at lysines K15 and K227 within synergy control motifs; the E2 SUMO-conjugating enzyme Ubc9 and E3 SUMO ligase PIASy enhance sumoylation, while SUMO protease SENP1 desumoylates Ets-1; sumoylation represses Ets-1 transcriptional activity; Ets-1 is also modified by K48-linked polyubiquitination and degraded via the 26S proteasome, independently of sumoylation sites.\",\n      \"method\": \"Mutagenesis (K→R substitutions), co-transfection with SUMO pathway components, reporter assays, proteasome inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-directed mutagenesis identifying acceptor sites, functional pathway component overexpression, proteasome experiments, single lab with multiple methods\",\n      \"pmids\": [\"16862185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PIASy is a specific SUMO-E3 ligase for Ets-1 and a novel interaction partner; PIASy represses Ets-1-dependent transcription independently of Ets-1 sumoylation status (requiring instead sumoylation of other factors).\",\n      \"method\": \"In vivo and in vitro sumoylation assays, mutagenesis, co-immunoprecipitation, reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro/in vivo sumoylation assays, Co-IP, reporter assays; consistent with [50], single lab\",\n      \"pmids\": [\"16729975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Ets-1 physically interacts with Blimp-1 and blocks Blimp-1 DNA binding activity and its ability to repress target genes (without affecting Blimp-1 protein levels), thereby limiting plasmacytic differentiation downstream of TLR9; Ets-1 also induces expression of Blimp-1 target genes including Pax-5.\",\n      \"method\": \"Co-immunoprecipitation, EMSA (DNA binding inhibition), reporter assays, gene expression analysis in KO B cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating physical interaction, EMSA showing functional inhibition of Blimp-1 DNA binding, KO cell validation, single lab\",\n      \"pmids\": [\"17977828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ets-1 DNA-binding affinity is allosterically regulated by a serine-rich region (SRR); multi-site phosphorylation of the flexible SRR in response to Ca2+ signaling enhances thermodynamic stability of the ETS domain and its inhibitory module and shifts Ets-1 to an inhibited conformation via transient intramolecular interactions between the SRR and the DNA-binding interface; paramagnetic relaxation enhancement NMR identified a preferential interaction surface.\",\n      \"method\": \"NMR spectroscopy (including paramagnetic relaxation enhancement), thermal/urea denaturation, DNA binding assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR-based structural and dynamic analysis with quantitative binding measurements and thermodynamic characterization, single lab\",\n      \"pmids\": [\"18692067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ets-1 forms a regulated homodimer on the stromelysin-1 promoter palindromic ETS-binding sites; the crystal structure of Ets-1 on this element reveals that homodimerization is mediated by the specific arrangement of two ETS-binding sites and requires the N-terminal flanking region; Ets-1 variants with mutations in this region lose the ability to dimerize on DNA and to transactivate the stromelysin-1 promoter.\",\n      \"method\": \"X-ray crystal structure determination, mutagenesis, EMSA, reporter transactivation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis and functional validation in a single rigorous study\",\n      \"pmids\": [\"18566588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In erythroid cells, Ets-1 is downregulated and exported from the nucleus via a leucine-rich nuclear export signal during differentiation; in megakaryocytes, Ets-1 remains nuclear; Ets-1 overexpression blocks erythroid maturation, upregulates GATA-2, and downregulates GATA-1; Ets-1 directly binds to and activates the GATA-2 promoter in vitro and in vivo.\",\n      \"method\": \"Nuclear export signal identification, subcellular fractionation, ChIP, reporter assays, overexpression in CD34+ progenitor cells\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP (in vivo binding), reporter assays, functional overexpression with lineage differentiation readouts, nuclear export signal identification, single lab\",\n      \"pmids\": [\"16294212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ets-1 is required for the development and suppressive function of natural regulatory T cells (Tregs); Ets-1-/- mice develop T cell-mediated autoimmunity with reduced Treg numbers; Ets-1-/- Tregs express low Foxp3 and show decreased in vitro suppression; Ets-1 interacts with the Foxp3 intronic enhancer and is required for demethylation of this regulatory sequence.\",\n      \"method\": \"Ets-1 knockout mouse, RAG2-/- reconstitution chimeras, fetal thymic organ culture, ChIP (Foxp3 enhancer), in vitro suppression assay, IBD transfer model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, ChIP demonstrating direct enhancer occupancy, functional suppression assay, multiple in vivo models, single lab\",\n      \"pmids\": [\"20855499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ets-1 and Ets-2 regulate miR-126 expression in endothelial cells; a genomic region (-71 to -100 bp upstream of the miR-126 transcriptional start site) containing an Ets binding site is critical for transactivation; mutations in the Ets binding site block transactivation; knockdown of Ets-1 and Ets-2 decreases miR-126 expression.\",\n      \"method\": \"Reporter assays with promoter deletion/mutagenesis, ChIP, Ets-1/Ets-2 knockdown\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with site mutagenesis, ChIP, and siRNA knockdown, single lab\",\n      \"pmids\": [\"20671229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ets-1 interacts with HDAC1; co-expression of Ets-1 with HDAC1 synergistically represses IL-10 transcription in Th1 cells; Ets-1 deficiency leads to increased histone H3 acetylation and reduced HDAC1 enrichment at Il10 regulatory regions.\",\n      \"method\": \"Co-immunoprecipitation (physical interaction), chromatin immunoprecipitation (HDAC1 enrichment, H3 acetylation), reporter assays, Ets-1 KO Th1 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating physical interaction, ChIP for chromatin changes, functional reporter assays, KO cell validation, single lab\",\n      \"pmids\": [\"22266280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ETS1 directly activates expression of ATXN2 by binding to an ETS-binding site in the ATXN2 promoter; endogenous ETS1 occupies the ATXN2 promoter (confirmed by supershift EMSA and ChIP); ETS1 overexpression increases ATXN2 expression, deletion of the ETS1-binding site abrogates this effect, and dominant-negative ETS1 or ETS1 shRNA reduce ATXN2 expression.\",\n      \"method\": \"EMSA with supershift assay, ChIP, luciferase reporter assays with promoter deletion, overexpression and dominant-negative/shRNA knockdown\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, supershift EMSA, reporter assays with mutagenesis, and gain/loss-of-function, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22914732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ets-1 physically and functionally interacts with NFAT proteins; Ets-1 is required for the recruitment of NFAT to the IL-2 promoter; nuclear Ets-1 exits the nucleus in response to calcium-dependent signals and competes with NFAT for binding to components of the NRON complex (a cytoplasmic trap for phosphorylated NFAT), thereby facilitating NFAT nuclear entry; Ets-1 deficiency impairs nuclear entry but not dephosphorylation of NFAT.\",\n      \"method\": \"Co-immunoprecipitation, ChIP (NFAT recruitment to IL-2 promoter), subcellular fractionation, nuclear entry assays in Ets-1-/- T cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, subcellular fractionation with functional outcome, KO validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24019486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VEGF stimulates ETS1 acetylation in endothelial cells; acetylated ETS1 has enhanced chromatin occupancy and binds BRD4, which recruits the RNAPII pause-release machinery to broadly increase RNAPII pause release at transcribed genes; this ETS1-BRD4 axis is required for endothelial cell angiogenic responses in vitro and in vivo.\",\n      \"method\": \"ChIP-seq, Co-immunoprecipitation, acetylation assays, dominant-negative and knockdown experiments, in vitro angiogenesis assays, in vivo angiogenesis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq, Co-IP, acetylation assays, in vivo validation with multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"28851877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The deubiquitinating enzyme Usp9x stabilizes Ets-1 by blocking its proteasomal destruction; Usp9x knockdown or inhibition reduces Ets-1 levels and suppresses Ets-1-driven NRAS expression and melanoma tumorigenicity; Usp9x and Ets-1 levels are coincidently elevated in metastatic melanoma.\",\n      \"method\": \"Ubiquitination assays, Usp9x knockdown/inhibition, Co-immunoprecipitation, gene expression analysis, in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assays, knockdown with functional rescue, in vivo tumor models, single lab with multiple methods\",\n      \"pmids\": [\"28198367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ETS-1 directly binds to p-Smad3 and prevents its ubiquitination and proteasomal degradation, thereby enhancing TGF-β1/Smad3 signaling and promoting hepatocyte apoptosis; TGF-β1 induces Ets-1 expression through p-Smad2/3 binding to the Ets-1 promoter.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, promoter binding analysis (ChIP for p-Smad2/3 at Ets-1 promoter), Ets-1 knockdown in primary hepatocytes and NASH mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination protection assay, ChIP, in vivo KO model, single lab\",\n      \"pmids\": [\"31189885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Endothelial-specific deletion of Ets-1 attenuates Ang II-induced cardiac fibrosis by inhibiting endothelial-to-mesenchymal transition (EndMT); Ets-1 knockdown in H5V cells blocks TGF-β1-induced EndMT with decreased expression of Snail, Slug, Twist, and ZEB1.\",\n      \"method\": \"Endothelial-specific conditional Ets-1 knockout mouse, Ang II infusion model, in vitro Ets-1 knockdown with EndMT markers\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined molecular markers, in vitro siRNA confirmation, single lab\",\n      \"pmids\": [\"30670148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EHF (ETS homologous factor) suppresses cancer progression by inhibiting ETS1-mediated activation of ZEB1 and ZEB2 expression; specifically, EHF-SF (short form) abrogates ETS1-mediated ZEB1 promoter activation by promoting ETS1 protein degradation.\",\n      \"method\": \"Reporter assays (ZEB1 promoter), EHF overexpression, ETS1 protein level analysis, in vivo xenograft metastasis model\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays, protein degradation measurement, in vivo metastasis assay, single lab\",\n      \"pmids\": [\"33712555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GATA4 and ETS1 physically interact (Co-IP) and co-operatively stimulate endothelial cell enhancer activity in reporter assays; ETS1 re-directs GATA4 pioneer binding to endothelial-selective genomic regions and augments GATA4's ability to open previously inaccessible chromatin; ETS1 is enriched at endothelial-selective GATA4-occupied enhancers adjacent to endocardial genes regulated by GATA4.\",\n      \"method\": \"Co-immunoprecipitation, lineage-specific ChIP (biotin-GATA4), ATAC-seq, single-cell RNA-seq, luciferase reporter assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — Co-IP, lineage-specific ChIP-seq, chromatin accessibility assay, and functional reporters, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36263775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"STAT6 and Ets-1 form a stable complex that modulates IL-4-induced Socs-1 expression in keratinocytes; co-expression of Ets-1 with STAT6 activation strongly inhibits Socs-1 promoter-luciferase reporter activity; a composite element with STAT6 and Ets binding sequences is required for IL-4 responsiveness.\",\n      \"method\": \"Co-immunoprecipitation (physical interaction), promoter deletion/mutagenesis, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP demonstrating physical interaction, promoter mutagenesis, reporter assays, single lab\",\n      \"pmids\": [\"15199062\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ETS1 is a sequence-specific transcription factor whose DNA-binding activity is regulated by an autoinhibitory module (involving marginally stable helices HI-1/HI-2 and C-terminal inhibitory sequences flanking the ETS domain), allosteric phosphorylation of a serine-rich region by CaMKII/MLCK (inhibitory) and ERK1/2 at Thr-38 (activating, promoting CBP/p300 recruitment via the PNT domain), sumoylation at K15/K227 (repressive) and ubiquitin-proteasome degradation (counteracted by deubiquitinase Usp9x); it cooperates with AML1/CBF through mutual relief of autoinhibition, interacts with numerous co-regulators (CBP/p300, MafB, Daxx/EAP1, EAPII, Sp100, HDAC1, Blimp-1, NFAT, GATA4, STAT6, nuclear receptors), and drives expression of MMP genes, uPA, VEGF targets, GATA-2, and other invasion/angiogenesis/immune-differentiation genes; in T cells it maintains survival, Foxp3/Treg development, IL-7R expression, and IL-2 production by facilitating NFAT nuclear entry, while in B cells it restrains plasmacytic differentiation by blocking Blimp-1 DNA binding, and in endothelial cells VEGF-stimulated ETS1 acetylation enhances its binding to BRD4 to broadly promote RNAPII pause release and angiogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ETS1 is a sequence-specific transcription factor, the mammalian ortholog of the avian v-ets oncogene, that integrates signaling inputs to control gene programs governing lymphocyte development, vascular biology, and tumor invasion [#0, #5]. Its DNA-binding activity is gated by an autoinhibitory module in which marginally stable N-terminal helices (HI-1, HI-2) pack against C-terminal inhibitory sequences and the ETS domain, an arrangement whose lability allows allosteric coupling of DNA binding to conformational change [#18]; multi-site phosphorylation of a flexible serine-rich region in response to Ca2+ signaling stabilizes this inhibited conformation through transient intramolecular contacts with the DNA-binding interface [#26]. Activating inputs converge through the unstructured N-terminal tail and adjacent PNT domain: ERK2 docks on this region and phosphorylates Thr-38, and MAPK phosphorylation enhances transactivation by promoting preferential recruitment of the CBP/p300 coactivators [#19, #20]. ETS1 is further controlled post-translationally by repressive sumoylation at K15/K227, by K48-linked polyubiquitination and proteasomal degradation, and by counteracting stabilization via the deubiquitinase Usp9x [#23, #35]. Autoinhibition is relieved cooperatively through partnership with core binding factor/AML1, which contacts both the exon VII inhibitory domain and the ETS domain to reciprocally stimulate DNA binding on the TCRβ enhancer [#4, #12]. ETS1 binds an extensive set of co-regulators that tune its output, including repressors (MafB, Daxx, EAPII, HDAC1, Blimp-1) and coactivators (Sp100, nuclear receptors), and drives invasion and angiogenesis genes such as uPA, MMP-9, and GATA-2 [#8, #9, #11, #28]. In T cells ETS1 maintains survival and supports Treg/Foxp3 development and IL-2 production by facilitating NFAT nuclear entry, while in B cells it restrains plasmacytic differentiation by blocking Blimp-1 DNA binding [#5, #29, #33, #25]. In endothelial cells, VEGF-stimulated acetylation enhances ETS1 chromatin occupancy and BRD4 binding to broadly promote RNAPII pause release and angiogenesis, and ETS1 cooperates with GATA4 to direct lineage-selective enhancer activation [#34, #39].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that the human gene encodes the mammalian ortholog of the v-ets oncogene defined ETS1 as a protooncogene-derived transcription factor worth dissecting mechanistically.\",\n      \"evidence\": \"cDNA sequencing and ORF analysis of human ETS1 versus chicken c-ets-1\",\n      \"pmids\": [\"2847145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence alone did not define DNA-binding specificity or regulatory mechanism\", \"No isoform or subcellular complexity addressed\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating multiple isoforms arising from splicing and phosphorylation, with distinct subcellular distributions, revealed that ETS1 activity is regulated at the level of protein form and localization.\",\n      \"evidence\": \"Monoclonal antibodies, subcellular fractionation, PCR and exon-specific antibodies\",\n      \"pmids\": [\"2189104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of isoform differences not resolved\", \"Kinases responsible for phosphorylation not identified\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Mapping AP-1-responsive and autoregulatory elements in the ETS1 promoter showed how ETS1 expression is itself wired into mitogenic signaling and positive feedback.\",\n      \"evidence\": \"Promoter cloning, deletion analysis and reporter transfection assays\",\n      \"pmids\": [\"1614856\", \"1945412\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reporter-based, single-lab evidence\", \"Endogenous chromatin context not tested\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Reconstitution of an ETS1-CBF ternary complex on the TCRβ enhancer established cooperative DNA binding as a core mechanism for ETS1 target selection.\",\n      \"evidence\": \"Recombinant protein binding, EMSA, oligonucleotide mutagenesis and binding kinetics\",\n      \"pmids\": [\"8264651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cooperativity not yet defined\", \"Whether autoinhibition is relieved by CBF not addressed here\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Knockout mice defined the physiological requirement for ETS1 in T cell survival/activation and in restraining terminal B cell differentiation, linking the transcription factor to lymphocyte biology.\",\n      \"evidence\": \"Blastocyst complementation, ES-cell gene targeting, flow cytometry, proliferation and apoptosis assays (two independent labs)\",\n      \"pmids\": [\"7566177\", \"7566176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating the phenotypes not identified\", \"Molecular mechanism of B cell restraint unknown at this stage\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identifying CBP/p300 binding and the NMR structure of the PNT domain showed that ETS1 transactivation operates via coactivator recruitment through a protein-interaction module, not the DNA-binding domain.\",\n      \"evidence\": \"Co-IP, GST pulldown, HAT assays, reporters; NMR structure of a PNT-domain fragment\",\n      \"pmids\": [\"9528793\", \"9770451\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation modulates CBP recruitment not yet established\", \"PNT-domain partners beyond CBP/p300 unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mapping the dual ETS1-AML1 contact points demonstrated mutual relief of autoinhibition as the mechanistic basis of cooperative transactivation.\",\n      \"evidence\": \"Co-IP, domain-deletion mapping, dominant-negative mutants, EMSA, reporter assays\",\n      \"pmids\": [\"10075931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the autoinhibited state not yet resolved\", \"Generality across other ETS1 partners not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery of repressive (MafB, Daxx, EAPII) and coactivating (Sp100) interactors, together with target promoters (uPA, MMP-9, MMP1), built the picture of ETS1 as a hub for context-dependent co-regulator control of invasion genes.\",\n      \"evidence\": \"Yeast hybrid screens, GST pulldown, Co-IP, reporter and migration assays\",\n      \"pmids\": [\"8620536\", \"10698492\", \"12743594\", \"11909962\", \"9639404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Many interactions rest on single-lab Co-IP/reporter data\", \"Endogenous co-occupancy on chromatin not demonstrated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Structural and biochemical dissection of the autoinhibitory module, ERK2 docking/Thr-38 phosphorylation, and phosphorylation-enhanced CBP/p300 recruitment defined the allosteric logic linking signaling to ETS1 output.\",\n      \"evidence\": \"NMR with relaxation/hydrogen exchange; in vitro kinase, fluorescence anisotropy, affinity chromatography, Co-IP and reporters\",\n      \"pmids\": [\"15591056\", \"17105191\", \"15572696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo dynamics of autoinhibition during signaling not directly measured\", \"Quantitative contribution of each PTM in cells unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of sumoylation, polyubiquitination/proteasomal degradation, and SUMO-pathway enzymes established post-translational turnover and SUMO marking as repressive controls on ETS1 abundance and activity.\",\n      \"evidence\": \"K→R mutagenesis, SUMO-pathway co-transfection, reporter assays, proteasome inhibition, Co-IP\",\n      \"pmids\": [\"16862185\", \"16729975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signals triggering sumoylation not defined\", \"Identity of the responsible ubiquitin ligase not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"NMR/PRE analysis of serine-rich-region phosphorylation, the crystal structure of DNA-dependent homodimerization, and the GATA-2 regulatory axis linked Ca2+ signaling, DNA architecture, and hematopoietic lineage choice to ETS1 conformation.\",\n      \"evidence\": \"NMR with PRE, denaturation and DNA-binding assays; X-ray crystallography, EMSA, ChIP and reporters\",\n      \"pmids\": [\"18692067\", \"18566588\", \"16294212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of the homodimeric mode unquantified\", \"Cross-talk between SRR phosphorylation and partner binding not fully mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"T-cell studies showed ETS1 acts through partner transcription factors—as a T-bet cofactor, an HDAC1-recruiting IL-10 repressor, a Foxp3-enhancer-occupying Treg determinant, and an NFAT nuclear-entry facilitator—explaining its immunological phenotypes mechanistically.\",\n      \"evidence\": \"KO mice, ChIP, Co-IP, subcellular fractionation, suppression and cytokine assays\",\n      \"pmids\": [\"15728239\", \"22266280\", \"20855499\", \"24019486\", \"17977828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single factor coordinates opposing activating/repressive roles unresolved\", \"Direct structural basis of NFAT/Blimp-1 binding not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"VEGF-induced acetylation coupling ETS1 to BRD4 and RNAPII pause release, and Usp9x-mediated stabilization driving NRAS in melanoma, revealed acetylation and deubiquitination as activating switches controlling angiogenic and oncogenic programs.\",\n      \"evidence\": \"ChIP-seq, Co-IP, acetylation/ubiquitination assays, knockdown, in vitro and in vivo angiogenesis and tumor models\",\n      \"pmids\": [\"28851877\", \"28198367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase responsible for ETS1 acetylation not identified\", \"Generality of pause-release mechanism beyond endothelium untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that ETS1 redirects GATA4 pioneer binding to open lineage-selective enhancers showed ETS1 functions as a partner that shapes chromatin accessibility for tissue-specific gene programs.\",\n      \"evidence\": \"Co-IP, lineage-specific ChIP, ATAC-seq, scRNA-seq, reporter assays\",\n      \"pmids\": [\"36263775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ETS1 biases pioneer binding not resolved\", \"Whether this cooperativity generalizes to other pioneer factors unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many regulatory layers—autoinhibition, multi-site phosphorylation, sumoylation, ubiquitination, acetylation, and dozens of partner interactions—are integrated in vivo to specify a given ETS1 target program in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM state to genome-wide occupancy\", \"Stoichiometry and temporal order of competing partner interactions unknown\", \"Acetyltransferase and ubiquitin ligase identities incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 9, 27, 28, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 27, 28, 32]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [12, 25, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 16, 28, 33]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 28, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 9, 28, 34]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 21, 29, 33]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [19, 20, 33, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [28, 39]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RUNX1\", \"CREBBP\", \"EP300\", \"MAFB\", \"DAXX\", \"BRD4\", \"GATA4\", \"NFAT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}